GSA Capital Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

GSA Capital Partners’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-33,529	Closed	-$53K	–	2132
2024 Q1	$53K	Sell	33,529 -300,944	-90%	-$446K	﹤0.01%	1532
2023 Q4	$287K	Buy	334,473 +120,797	+57%	+$106K	0.02%	1136
2023 Q3	$229K	Sell	213,676 -107,236	-33%	-$222K	0.02%	1227
2023 Q2	$831K	Sell	320,912 -108,557	-25%	-$387K	0.08%	418
2023 Q1	$1.75M	Buy	429,469 +300,190	+232%	+$1.39M	0.17%	105
2022 Q4	$649K	Buy	129,279 +118,220	+1,069%	+$741K	0.08%	438
2022 Q3	$145K	Buy	+11,059	New	+$167K	0.02%	1304
2021 Q1	–	Sell	-46,908	Closed	-$1.42M	–	1586
2020 Q4	$1.42M	Buy	+46,908	New	+$1.03M	0.23%	63

GSA Capital Partners's NGM Position: Q2 2024 in Review

GSA Capital Partners sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 33,529 shares — an estimated $53K sold.

GSA Capital Partners first reported a position in NGM in Q4 2020 and held it in 8 quarters. The position peaked at $1.75M in Q1 2023. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

GSA Capital Partners reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
GSA Capital Partners sold 33,529 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $53K.
GSA Capital Partners first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
GSA Capital Partners's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.75M in Q1 2023.
0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.